These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24160863)

  • 1. Vaccine development costs: a review.
    Waye A; Jacobs P; Schryvers AB
    Expert Rev Vaccines; 2013 Dec; 12(12):1495-501. PubMed ID: 24160863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines: from valuation to resource allocation.
    Bloom DE; Madhavan G
    Vaccine; 2015 Jun; 33 Suppl 2():B52-4. PubMed ID: 26022569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics and financing of vaccines for diarrheal diseases.
    Bartsch SM; Lee BY
    Hum Vaccin Immunother; 2014; 10(6):1568-81. PubMed ID: 24755623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the national pediatric vaccine stockpile: supply shortages, health impacts and cost consequences.
    Shrestha SS; Wallace GS; Meltzer MI
    Vaccine; 2010 Aug; 28(38):6318-32. PubMed ID: 20638451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious disease research investments: systematic analysis of immunology and vaccine research funding in the UK.
    Fitchett JR; Head MG; Atun R
    Vaccine; 2013 Dec; 31(50):5930-3. PubMed ID: 24176489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gold industry standard for risk and cost of drug and vaccine development revisited.
    Pronker ES; Weenen TC; Commandeur HR; Osterhaus AD; Claassen HJ
    Vaccine; 2011 Aug; 29(35):5846-9. PubMed ID: 21722688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 14. Opportunities for vaccine research in Europe.
    Gancberg D; Hoeveler A; Martini A; Draghia-Akli R
    Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the impact of wastage on pediatric vaccine immunization formulary costs using a vaccine selection algorithm.
    Jacobson SH; Karnani T; Sewell EC
    Vaccine; 2004 Jun; 22(17-18):2307-15. PubMed ID: 15149790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing a Global Vaccine-Development Fund.
    Plotkin SA; Mahmoud AA; Farrar J
    N Engl J Med; 2015 Jul; 373(4):297-300. PubMed ID: 26200974
    [No Abstract]   [Full Text] [Related]  

  • 20. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.